BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.

Diamond Pharma Services is a leading technical and scientific consulting group serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:

• Regulatory Affairs: From Product Concept to Registration and Beyond
• Product Development: Nonclinical, CMC and Clinical Aspects
• Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
• Compliance: GLP, GMP, GCP and QP Services
• Patient Information Leaflet Testing: Over 120 Tested with 100% Positive Agency Feedback

Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene therapy products).

We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 24 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.

Domainex has an internal pipeline of oncology targets which is based upon our unique technology Combinatorial Domain Hunting. These internal programmes are exclusively focused on nucleotide triphosphate binding domains (NTP domains) which are found in several important therapeutic targets of particular relevance to oncology. The current portfolio includes a number of lysine methyl transferases and a kinase IKK epsilon. Our IKK program is in lead optimisation. Domainex also offers services to Pharma using our unique patented technology called Combinatorial Domain Hunting (CDH) designed to rapidly express target proteins of all types including those which are technically challenging. We can also rapidly find novel robust hit like molecules with our platform technology LeadBuilder and then develop hits using highly experienced medicinal chemistry.

ECCRO is a specialist provider of Phase II-IV clinical trial services in India. Having customised industry best practices for India, we deliver the region�s clinical trial potential in terms of cost and time savings at international standards of ethical integrity and data quality. We do this by partnering with clinical trial sites such that they are staffed with a trained ECCRO site manager whose role is to support ECCRO trials at the site. ECCRO�s operational office is in Mumbai, India however its international base is in London, UK to facilitate sponsor interaction and liaison with partner CROs.

Innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.

gentronix provides services and solutions that help companies optimize the development of drugs and other chemicals, by reducing rates of attrition due to toxicity and ensuring safer products across a wide range of chemistry driven industries.

Our primary focus is on providing better hazard identification assays for genotoxicity through the use of our patented human cell GADD45a reporter assays GreenScreen HC® and BlueScreen HCTM. Gentronix provides contract services for genotoxicity in these and related assays including Comet and Micronucleus tests, as well as a wide range of ADME and predictive toxicity endpoints.

Reducing attrition rates due to toxicity concerns is critical to increasing the success of drug discovery projects. Identifying toxicity liability early allows valuable resources to be directed towards compounds more likely to advance to candidate selection and on to clinical evaluation.

Currently over 100 pharmaceutical and fine chemical companies in 17 countries have used the GreenScreen HC assay data as part of their genotoxicity profiling strategy.

QED Clinical Services is the first Contract Research Organisation (CRO) world-wide to make use of a Franchise model to conduct clinical trials globally. Whilst achieving superb quality throughout all Phases of the drug development process, this approach to conducting trials achieves considerable savings for the biopharmaceutical industry. In business since 2002, in many international studies and in rescue situations where large CROs have failed to deliver, QED has already proven that there is a true alternative to traditional full-service CROs available.

Stabilitech is a thermal stabilisation company. Through use of the company's proprietary technology, it has demonstrated thermal stability of live and inactivated viral vaccines and biopharmaceuticals including antibodies and proteins. The company uses excipients which are proprietary in this setting, have been used in clinical settings at least and have relatively low cost of goods. The stabilisation procedures are robust with few additional steps which can readily be integrated into existing cGMP production processes. Stabilitech's technology addresses one of the major issues related to vaccines and other biopharmaceuticals, the need for cold chain, thereby reducing cost and, most importantly, protecting efficacy. Stabilitech's aim is to apply this novel and proprietary technology to the stabilisation of key vaccines and biopharmaceuticals through partnerships.

Sygnature, founded in 2004, is a leading United Kingdom-based provider of integrated drug discovery services to the global pharmaceutical industry. Key areas of expertise include medicinal and synthetic chemistry, computational chemistry and bioscience. Sygnature´s team of more than 50 industry-experienced scientists add considerable value to our clients´ programmes by undertaking key elements of the drug discovery process, such as hit finding, hit-to-lead, lead optimisation and complete integrated drug discovery projects.

Services on offer at Sygnature include:

• Medicinal Chemistry
• Synthetic Chemistry
• Computational Chemistry
• Bioscience (in vitro biology and screening)
• Arrays and Libraries
• Process and Scale-up Chemistry
• ADME/Toxicology (via a strategic alliance with Cyprotex Discovery)